Table 1.
Characteristics of NSCLC Patients Undergoing EGFR-TKI Therapy.
| Variables | Metformin Use |
|||
|---|---|---|---|---|
| User | Nonuser | P | Total | |
| Patients, n (%) | 373 (100.0%) | 1260 (100.0%) | 1633 (100.0%) | |
| Sex, n (%) | .8065 | |||
| Female | 196 (52.5%) | 653 (51.8%) | 849 (52.0%) | |
| Male | 177 (47.5%) | 607 (48.2%) | 784 (48.0%) | |
| Age (years), n (%) | ||||
| 40-64 | 129 (34.6%) | 428 (34.0%) | 557 (34.1%) | |
| ≥65 | 244 (65.4%) | 832 (66.0%) | 1076 (65.9%) | |
| Median (IQR) | 69.0 (62.0-76.0) | 70.0 (61.0-76.0) | 70.0 (62.0-76.0) | |
| Urbanization, n (%) | .1460 | |||
| Very high | 118 (31.6%) | 372 (29.5%) | 490 (30.0%) | |
| High | 168 (45.0%) | 517 (41.0%) | 685 (41.9%) | |
| Moderate | 54 (14.5%) | 232 (18.4%) | 286 (17.5%) | |
| Low | 33 (8.8%) | 139 (11.0%) | 172 (10.5%) | |
| Income (NT$), n (%) | .7835 | |||
| 0 | 143 (38.3%) | 448 (35.6%) | 591 (36.2%) | |
| 1-15 840 | 70 (18.8%) | 238 (18.9%) | 308 (18.9%) | |
| 15 841-25 000 | 111 (29.8%) | 397 (31.5%) | 508 (31.1%) | |
| ≥25 000 | 49 (13.1%) | 177 (14.0%) | 226 (13.8%) | |
| Comorbidities, n (%) | ||||
| Hypertension | 292 (78.3%) | 900 (71.4%) | .0088* | 1192 (73.0%) |
| Stroke | 89 (23.9%) | 363 (28.8%) | .0606 | 452 (27.7%) |
| CAD | 142 (38.1%) | 514 (40.8%) | .3459 | 656 (40.2%) |
| COPD | 111 (29.8%) | 501 (39.8%) | .0005* | 612 (37.5%) |
| Renal insufficiency | 8 (2.1%) | 66 (5.2%) | .0116* | 74 (4.5%) |
| Smoking-related disorder | 64 (17.2%) | 331 (26.3%) | .0003* | 395 (24.2%) |
| CT/RT, n (%) | .0091* | |||
| CCRT | 135 (36.2%) | 566 (44.9%) | 701 (42.9%) | |
| CT | 129 (34.6%) | 409 (32.5%) | 538 (32.9%) | |
| RT | 34 (9.1%) | 102 (8.1%) | 136 (8.3%) | |
| Without CT or RT | 75 (20.1%) | 183 (14.5%) | 258 (15.8%) | |
| EGFR-TKI, n (%) | .0248* | |||
| Gefitinib | 215 (57.6%) | 633 (50.2%) | 848 (51.9%) | |
| Erlotinib | 129 (34.6%) | 487 (38.7%) | 616 (37.7%) | |
| Both | 29 (7.8%) | 140 (11.1%) | 169 (10.3%) | |
| EGFR-TKI response, n (%) | .0534 | |||
| Responder | 239 (64.1%) | 737 (58.5%) | 976 (59.8%) | |
| Nonresponder | 134 (35.9%) | 523 (41.5%) | 657 (40.2%) | |
| CT regimens before EGFR-TKI, n (%) | .3316 | |||
| ≤1 | 261 (70.0%) | 848 (67.3%) | 1109 (67.9%) | |
| ≥2 | 112 (30.0%) | 412 (32.7%) | 524 (32.1%) | |
| Follow-up duration (months) | ||||
| Median (IQR) | 22.9 (14.9-36.1) | 21.2 (13.5-33.5) | 21.5 (13.9-34.3) | |
Abbreviations: NSCLC, non–small cell lung cancer; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; IQR, interquartile range; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CT, chemotherapy; RT, radiotherapy; CCRT, concurrent chemoradiotherapy.
*
P < .05.